Shares of Auxilium Pharmaceuticals Inc. jumped 16 percent on news of a potential $485 million European partnership with Pfizer Inc. for its Xiaflex collagenase enzyme product, a deal that provides a substantial cash infusion up front and gives investors some much-needed reassurance of the product's market potential. (BioWorld Today)